ACIU AC Immune Corp: רווח נקי למניה ב-12 החודשים האחרונים

AC Immune (ACIU) wields significant influence in the brain degeneration segment, utilizing Morphomer for the synthesis of precision antibodies. The price indicator on the chart demonstrates an EPS TTM of 38.30, while the business relies on partnerships with pharma behemoths to fund its trials. The company develops vaccines that activate the immune response against brain plaques, addressing the global challenge of aging.

To minimize risks during long-term investing, it is critical to avoid purchasing assets at valuation peaks. The specifics of AC Immune (ACIU) involve the capital-intensive development of Alzheimer's disease vaccines based on the SupraAntigen platform. By analyzing the year-over-year rolling EPS chart, an investor can observe the net profit per share trend stripped of short-term noise. A stable trend in this metric confirms the financial stability of the biopharmaceutical business.